Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−35.4691 USD
−9.64 M USD
14.73 M USD
4.89 M
About NovaBay Pharmaceuticals, Inc.
Sector
CEO
Justin M. Hall
Headquarters
Emeryville
Website
Founded
2000
FIGI
BBG000PVPJT3
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NBY is 0.7198 USD — it has increased by 1.36% in the past 24 hours. Watch NovaBay Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange NovaBay Pharmaceuticals, Inc. stocks are traded under the ticker NBY.
NBY stock has fallen by −9.11% compared to the previous week, the month change is a 12.58% rise, over the last year NovaBay Pharmaceuticals, Inc. has showed a −93.39% decrease.
We've gathered analysts' opinions on NovaBay Pharmaceuticals, Inc. future price: according to them, NBY price has a max estimate of 6.60 USD and a min estimate of 0.85 USD. Watch NBY chart and read a more detailed NovaBay Pharmaceuticals, Inc. stock forecast: see what analysts think of NovaBay Pharmaceuticals, Inc. and suggest that you do with its stocks.
NBY stock is 7.06% volatile and has beta coefficient of 2.70. Track NovaBay Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is NovaBay Pharmaceuticals, Inc. there?
Today NovaBay Pharmaceuticals, Inc. has the market capitalization of 3.46 M, it has decreased by −2.48% over the last week.
Yes, you can track NovaBay Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
NovaBay Pharmaceuticals, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
NBY earnings for the last quarter are −0.60 USD per share, whereas the estimation was −0.30 USD resulting in a −96.72% surprise. The estimated earnings for the next quarter are −0.17 USD per share. See more details about NovaBay Pharmaceuticals, Inc. earnings.
NovaBay Pharmaceuticals, Inc. revenue for the last quarter amounts to 2.44 M USD, despite the estimated figure of 2.60 M USD. In the next quarter, revenue is expected to reach 3.15 M USD.
NBY net income for the last quarter is −1.21 M USD, while the quarter before that showed −1.58 M USD of net income which accounts for 23.53% change. Track more NovaBay Pharmaceuticals, Inc. financial stats to get the full picture.
No, NBY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 26.00 employees. See our rating of the largest employees — is NovaBay Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NovaBay Pharmaceuticals, Inc. EBITDA is −4.40 M USD, and current EBITDA margin is −32.60%. See more stats in NovaBay Pharmaceuticals, Inc. financial statements.
Like other stocks, NBY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NovaBay Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NovaBay Pharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NovaBay Pharmaceuticals, Inc. stock shows the sell signal. See more of NovaBay Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.